[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344395-105":59,"doc-detail-344395-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","contralateral-recurrent-upper-tract-urothelial-carcinoma-after-curative-surgery-multicentre-retrospective-cohort-study","Contralateral recurrent upper-tract urothelial carcinoma after curative surgery - multicentre retrospective cohort study","","Background: Contralateral recurrence of upper-tract urothelial carcinoma (UTUC) creates major clinical management uncertainty, especially for selecting the most appropriate surgical strategy. Objective: Compare oncological outcomes for patients with contralateral UTUC recurrence treated with second nephroureterectomy (NUR) or nephron-sparing surgery (NSS) versus primary NUR. Methods: Using a multicentre retrospective Taiwanese UTUC Registry cohort of 3159 patients (2018–2024), propensity score overlap weighting balanced baseline differences. Outcomes assessed OS, CSS, and BRFS. Results: After adjustment, survival outcomes were comparable across strategies; tumour stage, lymphovascular invasion, and multifocality showed stronger prognostic impact. Conclusion: Second NUR and NSS offered broadly similar survival to primary NUR, though NSS case scarcity limited precision.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/contralateral-recurrent-upper-tract-urothelial-carcinoma-after-curative-surgery-multicentre-retrospective-cohort-study/344395/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/contralateral-recurrent-upper-tract-urothelial-carcinoma-after-curative-surgery-multicentre-retrospective-cohort-study/344395.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was treatment compared for contralateral UTUC recurrence?","Question",{"text":112,"@type":113},"Patients were grouped as primary unilateral NUR, contralateral recurrence treated with a second NUR, or contralateral recurrence managed with nephron-sparing surgery (segmental ureterectomy or endoscopic ablation).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What outcomes were evaluated in the study?",{"text":117,"@type":113},"Overall survival (OS), cancer-specific survival (CSS), and bladder recurrence-free survival (BRFS).",{"name":119,"@type":110,"acceptedAnswer":120},"Did surgical modality (second NUR vs NSS) significantly change survival?",{"text":121,"@type":113},"After adjustment, both second NUR and NSS showed broadly comparable OS, CSS, and BRFS to primary NUR, although limited NSS sample size reduced statistical power for CSS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344395,1790261334,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Contralateral recurrent upper-tract urothelial carcinoma after curative surgery: a multicentre retrospective cohort study  \nYao-Lin Kao, I-Hsuan Alan Chen, Chia-Cheng Yu, Chao-Hsiang Chang,  \nHsi-Chin Wu, Ching-Chia Li, Wen-Jeng Wu, Yao-Chou Tsai, Chih-Chin Yu, Chung-You Tsai, Pai-Yu Cheng, Chao-Yuan Huang and Chien-Hui Ou  \nAbstract  \nBackground: Contralateral recurrence of upper-tract urothelial carcinoma (UTUC) presents a clinical challenge, with limited evidence regarding optimal surgical management.  \nObjective: To compare oncological outcomes among patients with contralateral UTUC recurrence managed by second nephroureterectomy (NUR) or nephron-sparing surgery (NSS), relative to those undergoing primary NUR.  \nDesign: A multicentre retrospective cohort study.  \nMethods: In this multicentre retrospective cohort, 3159 patients diagnosed with UTUC between 2018 and 2024 in the Taiwanese UTUC Registry were analysed. Patients undergoing curative-intent surgery were grouped as follows: unilateral UTUC treated with primary NUR; contralateral recurrence treated with a second NUR; and contralateral recurrence managed with nephron-sparing surgery (NSS; segmental ureterectomy or endoscopic ablation) . NUR was performed via open, laparoscopic, or robotic-assisted approaches. Outcomes included overall survival (OS), cancer-specific survival (CSS) and bladder recurrence-free survival (BRFS) . Propensity score-based overlap weighting adjusted for baseline differences.  \nResults: After adjustment, both second NUR and NSS achieved OS, CSS, and BRFS comparable to primary NUR. Tumour biology, including stage, lymphovascular invasion and multifocality, exerted greater prognostic impact than contralateral recurrence status or surgical modality. While the rarity of contralateral recurrence limited statistical power, particularly for CSS and in the NSS subgroup, the consistency of effect estimates supports the robustness of the observed trends.  \nConclusion: In this multicentre real-world cohort, second NUR and NSS for contralateral UTUC recurrence demonstrated broadly comparable survival outcomes to primary NUR, though the limited number of NSS cases and corresponding statistical power preclude firm conclusions.  \nPlain language summary  \nTreatment outcomes when cancer returns in the opposite kidney tube after curative surgery: results from a large multi-hospital study  \nWhy was the study done? Cancers of the upper urinary tract, which includes the kidney’s drainage tube, can sometimes come back on the opposite side after the first cancer is removed. When this happens, patients and doctors face difficult treatment choices. It isnot clear whether another major surgery or a smaller kidney-sparing operation is better. Until now, there has been little research to guide these decisions.  \nTherAdv Urol  \n2026, Vol. 18: 1–11  \nDOI: 10. 1177/ 17562872261419593 © The Author(s), 2026.  \nArticle reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nChien-Hui Ou  \nDepartment of Urology, Tainan Hospital, Ministry of Health and Welfare, No.  \n125, Jhongshan Rd. , West Central Dist. , Tainan City 700, Taiwan (R. O. C. )  \n[donou1969@yahoo.com.tw](donou1969@yahoo.com.tw)[ ](donou1969@yahoo.com.tw)Yao-Lin Kao  \nDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan  \nI-Hsuan Alan Chen Chia-Cheng Yu  \nDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan  \nChao-Hsiang Chang  \nDepartment of Urology, China Medical University and Hospital, Taichung, Taiwan  \nSchool of Medicine, China Medical University, Taichung, Taiwan  \nHsi-Chin Wu  \nDepartment of Urology, China Medical University and Hospital, Taichung, Taiwan  \nSchool of Medicine, China Medical University, Taichung, Taiwan Department of Urology, China Medical University Beigang Hospital, Yunlin, Taiwan  \nChing-Chia Li  \nDepartment of Urology, Kaohs","cbCaigyLcfJ3ifqk","https://ap.wps.com/l/cbCaigyLcfJ3ifqk","pdf",860753,11,"English","# Abstract\n## Background, Objective, Design\n## Methods\n## Results\n## Conclusion\n# Plain language summary","[{\"question\":\"How was treatment compared for contralateral UTUC recurrence?\",\"answer\":\"Patients were grouped as primary unilateral NUR, contralateral recurrence treated with a second NUR, or contralateral recurrence managed with nephron-sparing surgery (segmental ureterectomy or endoscopic ablation).\"},{\"question\":\"What outcomes were evaluated in the study?\",\"answer\":\"Overall survival (OS), cancer-specific survival (CSS), and bladder recurrence-free survival (BRFS).\"},{\"question\":\"Did surgical modality (second NUR vs NSS) significantly change survival?\",\"answer\":\"After adjustment, both second NUR and NSS showed broadly comparable OS, CSS, and BRFS to primary NUR, although limited NSS sample size reduced statistical power for CSS.\"}]","Contralateral recurrent upper-tract urothelial carcinoma after curative surgery - multicentre retrospective cohort study | PDF",1790053612,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b486d5c5bd7466a054214e655b9523c1.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b3714714ad43ca6cb23e5df7555d815.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3037080fe186f96bed8da08338c35682.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38a5731ad353ac05a591d6268709d486.webp",980,1306]